Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Edaravone oral - Treeway

Drug Profile

Edaravone oral - Treeway

Alternative Names: FAB-122; FNP-122; TW-001; TW-101

Latest Information Update: 16 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Treeway
  • Developer Ferrer; Treeway
  • Class Anti-ischaemics; Antidementias; Antihaemorrhagics; Antiparkinsonians; Hepatoprotectants; Neuroprotectants; Pyrazolones; Small molecules; Vascular disorder therapies
  • Mechanism of Action Antioxidants; Free radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity No

Highest Development Phases

  • Phase III Amyotrophic lateral sclerosis
  • Phase II Alzheimer's disease

Most Recent Events

  • 22 Feb 2024 Ferrer terminates the phase III ADOREXT trial in Amyotrophic lateral sclerosis in Spain, Italy, France, Belgium, Germany, the Netherlands, Poland, Ireland and Sweden due to lack of efficacy of Edaravone (NCT05866926) (EudraCT2022-003050-32)
  • 10 Jan 2024 Safety and efficacy data from the phase III ADORE trial in Amyotrophic lateral sclerosis released by Ferrer
  • 27 Aug 2023 TW 001 licensed to Specialised Therapeutics Asia in Australia and New Zealand
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top